

2017

META-ANALYSIS COMPARING BIORESORBABLE VS. DRUG-ELUTING STENTS

King, N::0000-0001-6989-5760

<http://hdl.handle.net/10026.1/11116>

CARDIOLOGY

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

META-ANALYSIS COMPARING BIORESORBABLE VS. DRUG-ELUTING STENTS

Nicola King¹, Cherith Wood¹ and Neil A Smart²

¹School of Biomedical and Healthcare Sciences, PUPSMD, Plymouth University, Drake Circus, Plymouth. PL4 8AA. UK.

²School of Science and Technology, University of New England, Armidale. NSW 2351. Australia.

Background: Some concerns have been raised about the occurrence of acute, late or very late stent thrombosis with drug eluting stents (DES) [1]. To address this bioresorbable stents (BRS) have been introduced; however, there are few studies comparing the efficacy of BRS vs. DES.

Objectives: The aim of this meta-analysis was to compare the effects of BRS vs. DES on a range of clinical outcomes.

Methods: To identify potential randomised clinical trials systematic searches were carried out in EMBASE, PubMed, Web of Science and the Cochrane Central Registry of Controlled Trials (CENTRAL) (until 24/02/2017) searching for “bioresorbable” and “drug eluting stent”. This was followed by a meta-analysis investigating device success (no use of an unassigned device), mortality, target lesion revascularisation (TLR), incidence of myocardial infarction (MI), target lesion failure (TLF), target vessel revascularisation (TVR), early thrombosis (equal to or less than 30 days), late thrombosis (>30 days), in segment late lumen loss (change in minimal lumen diameter post-procedure to 6-13 months) and minimum luminal diameter post-procedure (MLDPP) (in device).

Results: Seven studies involving 4914 participants were identified. There were no significant differences in the incidences of early thrombosis (odds ratio (OR) 1.67 [95% confidence interval (CI) 0.79-3.54, p=0.18]), late thrombosis (OR 1.11 [95% CI 0.51-2.42, p=0.8]), mortality, MI, TLR, TLF, and TVR for BRS vs. DES. Device success (OR 0.16 [95% CI 0.08-0.31, p<0.00001]) and MLDPP (in device) (mean difference (MD) -0.11mm [95% CI -0.14-0.07, p<00001]) were significantly lower and in segment late lumen loss (MD 0.04mm [95% CI 0.00-0.07, p=0.04) was significantly higher for BRS.

Conclusions: BRS use did not reduce the incidence of thrombosis or revascularisation and was associated with lower device success, higher in segment late lumen loss and lower MLDPP (in device).

Reference

Brie D et al (2016) Int J Cardiol. 215, 47-59.